Paris, France

Sylvie Sordello

USPTO Granted Patents = 2 


Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 17(Granted Patents)


Location History:

  • Montrabe, FR (2012)
  • Paris, FR (2013)

Company Filing History:


Years Active: 2012-2013

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Sylvie Sordello: Innovator in FGF Receptor Technology

Introduction

Sylvie Sordello is a prominent inventor based in Paris, France. She has made significant contributions to the field of biotechnology, particularly in the development of modified soluble FGF receptor Fc fusions. With a total of two patents to her name, her work has the potential to impact therapeutic applications significantly.

Latest Patents

Sylvie Sordello's latest patents include innovative methods related to modified soluble FGF receptor Fc fusions. The first patent focuses on a fusion of a soluble fragment or domain of the FGF receptor with an Fc region of an immunoglobulin. This invention aims to enhance biological activity, including antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) activities. The second patent mirrors the first, emphasizing the improved biological activity of these modified fusions and detailing the compositions and methods for producing such molecules.

Career Highlights

Sylvie Sordello is currently associated with Aventis Pharma S.A., where she continues to advance her research in biotechnology. Her work has garnered attention for its innovative approach to enhancing the efficacy of therapeutic proteins.

Collaborations

Throughout her career, Sylvie has collaborated with notable colleagues, including Francis Blanche and Mark Nesbit. These partnerships have contributed to her success and the advancement of her research.

Conclusion

Sylvie Sordello is a trailblazer in the field of biotechnology, with her patents reflecting her commitment to innovation. Her work on modified soluble FGF receptor Fc fusions showcases her expertise and potential to influence future therapeutic developments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…